Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riluzole - Aquestive Therapeutics

Next Previous
Drug Profile

Riluzole - Aquestive Therapeutics

Alternative Names: AQST-117; Emylif; Exservan; Riluzole oral soluble film; Riluzole OSF

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MonoSol Rx
  • Developer Aquestive Therapeutics
  • Class Benzothiazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Registered Amyotrophic lateral sclerosis

Most Recent Events

  • 14 Feb 2025 Aquestive Therapeutics files for a NDA withdrawal application with the FDA in US for Amyotrophic lateral sclerosis prior to February 2025
  • 14 Feb 2025 Withdrawn for Amyotrophic lateral sclerosis (Adjunctive treatment) in USA (PO)
  • 31 Dec 2022 Registered for Amyotrophic lateral sclerosis in European Union prior to December 2022 (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top